Okay. This is Bruno, I'm going to cover your questions. So, in regards to the Liquids FRE margin, what happened was a combination of some mark-to-market impact and some small redemptions that we had that accumulated over the past few quarters. So, revenues were a little bit down when you compare on a year-over-year basis. And the other thing was that once we had the decline in the Advisory revenue, the cost allocation for the corporate center was rebalanced. So, that means that the other verticals had to cope with more of the corporate center costs. So, it ended up affecting the margin of the Liquid business a little bit more this quarter, right? Going forward, I mean, if you look into the fourth quarter, there was an appreciation in AUM in the third quarter. So, we're likely going to have a little bit more of a tailwind from revenues in Liquids there. But I wouldn't expect margins from Liquids to change materially. I mean, from the levels that we had this quarter, probably improve a little bit, but not substantially, right? In terms of Advisory, what we have been saying is that last year was a very strong year. So, we had around $60 million in revenue. This year, we already -- when we came into the year, we knew that the pipeline was looking a little bit slower for '22. For '23, when we look at the pipeline of deals for '23, the ones that are able to be closed in '23, I would say, probably we are somewhere in the middle between '22 and '21. Difficult to say if it's exactly in the mid or if it's a little bit lower, then the mid were higher, but today, from the vantage point that we have today, the expectation is that we should have a year that should be between '21 and '22 from a revenue standpoint in the Advisory business. So, I don't know if I covered all your questions, but those are the ones that I had here.